Laura Brass
Direttore/Membro del Consiglio presso Immunitas Therapeutics, Inc.
Posizioni attive di Laura Brass
Società | Posizione | Inizio | Fine |
---|---|---|---|
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Investitore di Private Equity | 01/10/2018 | - |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Direttore/Membro del Consiglio | 11/09/2019 | - |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - | - |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Laura Brass
Precedenti posizioni note di Laura Brass
Società | Posizione | Inizio | Fine |
---|---|---|---|
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investitore di Private Equity | 01/01/2015 | 30/09/2018 |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - | - |
Elixir Pharmaceuticals, Inc.
Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
TriNetX, LLC
TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Investitore di Private Equity | 01/01/2005 | 06/10/2010 |
Corporate Officer/Principal | 07/10/2010 | - | |
Vendite & Marketing | 06/10/2010 | 07/10/2010 |
Formazione di Laura Brass
The University of Chicago | Doctorate Degree |
University of Missouri | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Svizzera | 2 |
Posizioni
Director/Board Member | 4 |
Private Equity Investor | 3 |
Corporate Officer/Principal | 3 |
Settori
Finance | 4 |
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 9 |
---|---|
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Elixir Pharmaceuticals, Inc.
Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA. | Miscellaneous |
TriNetX, LLC
TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Health Services |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Finance |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Health Technology |
ESCAPE Bio, Inc.
ESCAPE Bio, Inc. BiotechnologyHealth Technology ESCAPE Bio, Inc. is a preclinical stage biopharmaceutical company. It focuses on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. The company was founded by Robert Mahley and Yadong Huang in 2015 and is headquartered in San Francisco, CA. | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Laura Brass
- Esperienza